Objective: To prepare hTERT antisense oligodeoxynucleotide (ASODN) loaded polybutylcyanoacrylate nanoparticles (PBCA-NP) and evaluate the efficacy to inhibit glioma growth in vitro.
Methods: hTERT ASODN-PBCA-NP was prepared using the emulsion polymerization method. The size and morphology were observed by transmission electron microscopy. The drug loading and entrapment efficiency of ASODN in the nanoparticles were measured by UV spectra. The viability of SHG44 glioma cells was detected by MTT assay, cell cycle was determined by flow cytometry. The expression of hTERT mRNA was measured by RT-PCR, telomerase protein expression was measured by immunocytochemical analysis.
Results: The nanoparticles were discrete and uniform spheres with average diameter of 120 nm, with drug loading and entrapment efficiency of 71.17% and 95.20%, respectively. Zeta potential was +41.3 mV. SHG44 cells treated by ASODN-NP showed reduced hTERT mRNA and reduced telomerase protein expression levels, reduced cell viability, increased percentages of cells at G0/G1 and G2/M phases and decreased percentages of cells at S phase compared to control groups.
Conclusion: PBCA nanoparticles loaded with antisense oligodeoxynucleotide of hTERT can inhibit the expression of hTERT and inhibit the viability of glioma cells.